Suppr超能文献

替加环素推定分类的万古霉素药敏试验结果分析。

Analysis of Vancomycin Susceptibility Testing Results for Presumptive Categorization of Telavancin.

作者信息

Mendes Rodrigo E, Farrell David J, Flamm Robert K, Sader Helio S, Jones Ronald N

机构信息

JMI Laboratories, North Liberty, Iowa, USA

JMI Laboratories, North Liberty, Iowa, USA.

出版信息

J Clin Microbiol. 2015 Aug;53(8):2727-30. doi: 10.1128/JCM.00611-15. Epub 2015 May 27.

DOI:10.1128/JCM.00611-15
PMID:26019194
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4508411/
Abstract

Scattergrams between vancomycin and telavancin demonstrated susceptibility agreement rates of 99.96, 99.65, and 100.00% for Staphylococcus aureus, Enterococcus faecalis, and streptococci, respectively. A single very major error was obtained against E. faecalis, while vancomycin-intermediate S. aureus (VISA) and vancomycin-resistant and teicoplanin-susceptible (VanB phenotype) E. faecalis were responsible for major and minor errors. These results support the use of vancomycin to infer telavancin susceptibility among indicated pathogens, except VISA, which should be tested for telavancin susceptibility.

摘要

万古霉素与替考拉宁之间的散点图显示，金黄色葡萄球菌、粪肠球菌和链球菌对替考拉宁的药敏一致率分别为99.96%、99.65%和100.00%。针对粪肠球菌出现了1个非常主要的错误，而万古霉素中介金黄色葡萄球菌（VISA）以及万古霉素耐药且替考拉宁敏感（VanB表型）的粪肠球菌导致了主要和次要错误。这些结果支持使用万古霉素来推断指定病原体对替考拉宁的药敏情况，但VISA除外，VISA应检测其对替考拉宁的药敏。

相似文献

1
Analysis of Vancomycin Susceptibility Testing Results for Presumptive Categorization of Telavancin.
J Clin Microbiol. 2015 Aug;53(8):2727-30. doi: 10.1128/JCM.00611-15. Epub 2015 May 27.
2
Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection.
Antimicrob Agents Chemother. 2011 Feb;55(2):867-73. doi: 10.1128/AAC.00933-10. Epub 2010 Nov 15.
3
Telavancin Activity against gram-positive bacteria isolated from patients with skin and skin-structure infections.
J Chemother. 2010 Oct;22(5):304-11. doi: 10.1179/joc.2010.22.5.304.
4
In vitro activities of telavancin and vancomycin against biofilm-producing Staphylococcus aureus, S. epidermidis, and Enterococcus faecalis strains.
Antimicrob Agents Chemother. 2009 Jul;53(7):3166-9. doi: 10.1128/AAC.01642-08. Epub 2009 May 18.
5
In vitro activity of telavancin and comparators against selected groups of Gram-positive cocci.
Int J Antimicrob Agents. 2013 Mar;41(3):213-7. doi: 10.1016/j.ijantimicag.2012.10.016. Epub 2013 Jan 6.
6
Telavancin: mechanisms of action, in vitro activity, and mechanisms of resistance.
Clin Infect Dis. 2015 Sep 15;61 Suppl 2:S58-68. doi: 10.1093/cid/civ534.
7
Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus.
J Antimicrob Chemother. 2006 Dec;58(6):1177-84. doi: 10.1093/jac/dkl424. Epub 2006 Oct 24.
8
In vitro activity of dalbavancin and telavancin against staphylococci and streptococci isolated from patients in Canadian hospitals: results of the CANWARD 2007-2009 study.
Diagn Microbiol Infect Dis. 2011 Mar;69(3):342-7. doi: 10.1016/j.diagmicrobio.2010.10.031.
9
Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.
J Antimicrob Chemother. 2009 Jun;63(6):1191-9. doi: 10.1093/jac/dkp126. Epub 2009 Apr 15.
10
Activity of telavancin against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) in vitro and in an in vivo mouse model of bacteraemia.
J Antimicrob Chemother. 2010 Apr;65(4):725-8. doi: 10.1093/jac/dkq028. Epub 2010 Feb 5.

引用本文的文献

1
Emergence of Clinical Clostridioides difficile Isolates With Decreased Susceptibility to Vancomycin.
Clin Infect Dis. 2022 Jan 7;74(1):120-126. doi: 10.1093/cid/ciaa912.
2
Intrathecal Antibacterial and Antifungal Therapies.
Clin Microbiol Rev. 2020 Apr 29;33(3). doi: 10.1128/CMR.00190-19. Print 2020 Jun 17.
3
Evaluation of telavancin susceptibility in isolates of Staphylococcus aureus with reduced susceptibility to vancomycin.
Eur J Clin Microbiol Infect Dis. 2019 Dec;38(12):2323-2330. doi: 10.1007/s10096-019-03683-z. Epub 2019 Aug 24.
4
Efficacy of Telavancin Alone and in Combination with Ampicillin in a Rat Model of Enterococcus faecalis Endocarditis.
Antimicrob Agents Chemother. 2017 May 24;61(6). doi: 10.1128/AAC.02489-16. Print 2017 Jun.
5
How to measure the impacts of antibiotic resistance and antibiotic development on empiric therapy: new composite indices.
BMJ Open. 2016 Dec 16;6(12):e012040. doi: 10.1136/bmjopen-2016-012040.

本文引用的文献

1
Update of the telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2013), when applying the revised susceptibility testing method.
Diagn Microbiol Infect Dis. 2015 Apr;81(4):275-9. doi: 10.1016/j.diagmicrobio.2014.12.011. Epub 2014 Dec 31.
2
Baseline activity of telavancin against Gram-positive clinical isolates responsible for documented infections in U.S. hospitals (2011-2012) as determined by the revised susceptibility testing method.
Antimicrob Agents Chemother. 2015 Jan;59(1):702-6. doi: 10.1128/AAC.04052-14. Epub 2014 Oct 27.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验